一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Amivantamab；Osimertinib；Lazertinib；Placebo，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、长沙、常州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Amivantamab；Osimertinib；Lazertinib；Placebo · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Friendship Hospital Capital Medical University · 北京
- Beijing Cancer Hospital Respiratory Medicine Department II · 北京
- Beijing Cancer Hospital Respiratory Medicine Department I · 北京
- Chinese PLA General Hospital · 北京
- Beijing Chest hospital, Capital medical university · 北京
- Jilin cancer hospital · 长春
- Hunan Cancer hospital Thoracic Medicine Department II · 长沙
- Hunan Cancer hospital Thoracic Medicine Department I · 长沙
- The First People's Hospital Of Changzhou · 常州
- Sichuan Cancer Hospital · 成都
- West China Hospital Sichuan University · 成都
- Southwest Hospital · 重庆
- The First Affiliated Hospital Sun Yat sen University · 广州
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University · 广州
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 杭州
- The Second Affiliated Hospital of Zhejiang University College of Medicine · 杭州
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin medical university cancer hospital · 哈尔滨
- Huizhou Municipal Central Hospital · 惠州
- Taizhou Hospital of Zhejiang Province · 临海
- Nantong Tumor Hospital · 南通
- Ruijin Hospital Shanghai Jiao Tong University · 上海
- Shanghai Chest Hospital · 上海
- Fudan University Shanghai Cancer Center · 上海
- Shanghai East Hospital · 上海
- Shengjing Hospital Of China Medical University · 沈阳
- Tianjin Medical University General Hospital · 天津
- Cancer Hospital of Xinjiang Medical University · 乌鲁木齐
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology · 武汉
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Yantai Yuhuangding Hospital · 烟台
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
- * The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the Un
- * Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid \[ctDNA\], digital droplet polymerase chain reaction \[ddPCR\], and pha
- * Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
- * Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiat
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04487080；登记信息更新于 2026-09-28。